Overview & Classification
Chondrosarcoma is the third most common primary malignant bone tumour after multiple myeloma and osteosarcoma, accounting for approximately 20–27% of all primary bone sarcomas. It is a malignant tumour arising from chondrogenic cells that produces cartilage matrix but not bone. Unlike osteosarcoma and Ewing sarcoma, chondrosarcoma is predominantly a tumour of adult and middle-aged patients, with a peak incidence in the 4th–6th decades. It is characterised by relative resistance to conventional chemotherapy and radiotherapy, making surgery the primary — and often sole — treatment modality. The spectrum of chondrosarcoma ranges from low-grade lesions with indolent behaviour to high-grade tumours with aggressive metastatic potential.
| Subtype | Frequency | Location / Origin | Key Features | Prognosis |
|---|---|---|---|---|
| Central (conventional) — Grade 1, 2, 3 | ~75% of all chondrosarcomas | Intramedullary; pelvis, proximal femur, proximal humerus, ribs, distal femur; de novo or from malignant transformation of enchondroma | Grade 1 (atypical cartilaginous tumour/ACT): low cellularity, abundant matrix, no necrosis, few mitoses; Grade 2: moderate cellularity, focal necrosis; Grade 3: high cellularity, marked nuclear atypia, necrosis, mitoses; IDH1/IDH2 mutations in ~55% of cases | Grade 1: 10-year OS ~90%; Grade 2: ~60–70%; Grade 3: ~30–40%; metastases rare in Grade 1, common in Grade 3 |
| Secondary peripheral (from osteochondroma) | ~15% | Arises in the cartilage cap of an osteochondroma (solitary or HME); pelvis, shoulder girdle, proximal femur | Typically low-grade (Grade 1–2); enlarging cartilage cap >2 cm in an adult = suspicious; EXT1/EXT2 mutations; treatment — wide excision | Generally favourable; lower grade than central; local recurrence after incomplete excision is the main risk |
| Dedifferentiated chondrosarcoma | ~10% | Intramedullary; occurs when a low-grade chondrosarcoma undergoes dedifferentiation to a high-grade non-cartilaginous sarcoma (osteosarcoma, fibrosarcoma, or pleomorphic sarcoma); bimorphic appearance on imaging — low-grade cartilaginous component + high-grade destructive component | Radiologically: chondroid calcification (low-grade area) + aggressive lysis/soft tissue mass (dedifferentiated area); on histology: abrupt transition between well-differentiated cartilage and high-grade sarcoma; IDH1/IDH2 and TP53 mutations | Very poor prognosis — 5-year OS ~10–20%; most patients die of distant metastases; chemotherapy may be used for the high-grade component (as for osteosarcoma/MFH protocol) |
| Clear cell chondrosarcoma | ~1–2% | Epiphyseal location (important — cartilage tumour in the epiphysis); proximal femur, proximal humerus; low-grade | Cells with clear cytoplasm (glycogen-rich); may mimic chondroblastoma on histology; epiphyseal location is a clue; low malignant potential; wide excision curative | Good prognosis if adequately excised; local recurrence after inadequate excision may dedifferentiate |
| Mesenchymal chondrosarcoma | ~1–2% | Bone AND soft tissue; young adults; jaw, ribs, spine; 40% extraosseous | Biphasic histology — islands of well-differentiated hyaline cartilage within sheets of small round blue cells (haemangiopericytoma-like pattern); HEY1-NCOA2 gene fusion is diagnostic; CD99 negative; IDH1/IDH2 negative | Aggressive; late metastases (may occur 20+ years after diagnosis); 5-year OS ~50–60%; chemotherapy used (similar to Ewing/RMS protocols) |
Clinical Presentation & Imaging
- Clinical features: slowly progressive, deep, aching pain — often present for months to years before diagnosis (low-grade chondrosarcoma is an indolent tumour); pain in an adult with a cartilage lesion is the most important red flag for malignant transformation from enchondroma; palpable mass in some cases (especially peripheral secondary chondrosarcoma from osteochondroma); pathological fracture in aggressive Grade 3 or dedifferentiated tumours; neurological symptoms if spinal or pelvic involvement; NOTE — Grade 1 central chondrosarcoma (ACT) may be painless and discovered incidentally, creating diagnostic difficulty in distinguishing it from enchondroma
- Plain radiographic features: ring-and-arc (arcuate) calcification within a lobular lytic lesion — the cartilage matrix pattern; endosteal scalloping — crucial finding; the depth and extent of endosteal scalloping is the most important plain radiograph measurement for distinguishing enchondroma from chondrosarcoma (>2/3 cortical thickness scalloping = chondrosarcoma); cortical thickening or destruction; periosteal reaction in higher-grade tumours; soft tissue mass (Grade 2–3 and dedifferentiated)
- MRI features: T2/STIR — high signal lobular lesion (water content of hyaline cartilage); ring-and-arc enhancement on gadolinium-enhanced T1 (peripheral and septal enhancement around cartilage lobules); features favouring malignancy over enchondroma — intralesional cysts or necrosis, cortical breakthrough, extraosseous soft tissue extension, high signal extending beyond the lesion; the pattern of enhancement does NOT reliably distinguish low-grade chondrosarcoma from enchondroma — this distinction requires combined clinical, radiological, and histological assessment at a specialist centre
The Enchondroma vs Chondrosarcoma Challenge
The distinction between enchondroma and Grade 1 central chondrosarcoma (atypical cartilaginous tumour) is one of the most diagnostically challenging problems in orthopaedic oncology. There is a recognised diagnostic spectrum from `borderline` lesions through to unequivocal malignancy, and histological assessment alone is often insufficient — a multidisciplinary correlation of clinical, radiological, and histological features is required.
| Assessment Domain | Enchondroma | Grade 1 Chondrosarcoma (ACT) |
|---|---|---|
| Pain (key clinical differentiator) | Asymptomatic (incidental) or pain only with pathological fracture | Deep aching pain at rest in an adult — most important symptom; pain not explained by fracture |
| Size | <5 cm | >5 cm (high risk); size alone not diagnostic |
| Endosteal scalloping depth | <2/3 cortical thickness | >2/3 cortical thickness — KEY radiographic finding |
| Growth on serial imaging | Stable over years | Progressive enlargement over time |
| MRI signal | High T2 lobular lesion; ring-and-arc enhancement; no cysts or necrosis; no cortical breach | Intralesional cysts/necrosis; cortical breach; extraosseous extension; spreading signal on T2 |
| Location | Distal skeleton (hand) — low risk; long bones — intermediate | Proximal/axial skeleton — pelvis, proximal femur, shoulder girdle, ribs — HIGH risk for malignancy |
| Histology | Paucicellular hyaline cartilage; chondrocytes in lacunae; minimal atypia; no binucleated cells; no necrosis | Hypercellular cartilage; mild-to-moderate nuclear atypia; binucleated cells; permeation of pre-existing bone trabeculae; HOWEVER — Grade 1 histology alone cannot distinguish from enchondroma without clinical/imaging correlation |
- WHO 2020 classification change: the term `Grade 1 chondrosarcoma` of long bones and the appendicular skeleton has been renamed `atypical cartilaginous tumour (ACT)`; this reflects the fact that these lesions virtually never metastasise from long bone locations and curettage (intralesional) is often adequate treatment; however, Grade 1 chondrosarcoma of the pelvis, axial skeleton, and skull base retains the malignant classification — these DO require wide excision due to local recurrence risk and occasional metastatic potential in these locations
Biopsy & Surgical Management
- Biopsy principles: biopsy of cartilage tumours is technically challenging — the cartilage matrix is paucicellular and sampling error is common; biopsy results must ALWAYS be correlated with clinical and imaging findings; an `enchondroma` on biopsy does not exclude chondrosarcoma if the imaging and clinical features are suspicious; the biopsy must be planned with the definitive surgical approach in mind (the biopsy tract must be within the planned resection zone); do NOT biopsy a peripheral osteochondroma cap or an obviously benign lesion — surgical excision is both diagnostic and therapeutic
- Surgical management by grade and location: Grade 1 ACT (long bone appendicular) — intralesional curettage + cementation (adequate for most cases; wide excision reserved for large lesions with aggressive features or those causing fracture risk); Grade 1 chondrosarcoma (pelvis/axial) — WIDE excision required (local recurrence risk is higher; pelvic excision challenging); Grade 2 and Grade 3 — wide surgical excision is mandatory; the surgical margin quality is the most important determinant of local recurrence risk in all grades; adjuvant chemotherapy has no proven benefit for conventional chondrosarcoma; radiotherapy has limited efficacy for conventional chondrosarcoma (cartilage is relatively radioresistant)
- Chondrosarcoma is surgery-only: conventional chondrosarcoma (Grade 1, 2, 3 central/peripheral) does NOT respond to conventional chemotherapy or radiotherapy; surgery is the only effective treatment modality; this fundamental difference from osteosarcoma and Ewing sarcoma means that there is no role for neoadjuvant chemotherapy in conventional chondrosarcoma; exceptions — dedifferentiated chondrosarcoma (the high-grade dedifferentiated component may be treated with osteosarcoma-type chemotherapy protocols) and mesenchymal chondrosarcoma (may receive Ewing/rhabdomyosarcoma protocols)
Exam Pearls
- Chondrosarcoma: 3rd most common primary bone malignancy; adults 4th–6th decade; surgery ONLY (no effective chemotherapy or RT for conventional chondrosarcoma); grade determines prognosis (Grade 1 5-year OS 90%; Grade 3 30%)
- Central chondrosarcoma: intramedullary; ring-and-arc calcification; pelvis + proximal femur most common; IDH1/IDH2 mutations (~55%); Grade 1 = ACT in appendicular skeleton (curettage) vs pelvis (wide excision)
- ACT/Grade 1 long bone: WHO 2020 — renamed atypical cartilaginous tumour; virtually never metastasises from appendicular long bones; intralesional curettage adequate; Grade 1 pelvis/axial — still requires wide excision
- Dedifferentiated chondrosarcoma: bimorphic — low-grade cartilage + high-grade non-cartilaginous sarcoma at abrupt transition; IDH + TP53 mutations; 5-year OS ~10–20%; worst prognosis; chemotherapy for high-grade component
- Clear cell chondrosarcoma: EPIPHYSEAL location (unique among chondrosarcomas and cartilage tumours generally); low-grade; wide excision curative; clear cytoplasm on histology; mimics chondroblastoma
- Mesenchymal chondrosarcoma: young adults; biphasic histology (cartilage islands + small round blue cells); HEY1-NCOA2 fusion; late metastases (20+ years); chemotherapy used
- Secondary peripheral chondrosarcoma: from osteochondroma cap; cap >2 cm in adult = suspicious; wide excision; EXT1/EXT2 mutations; generally low-grade
- Endosteal scalloping >2/3 cortical width: KEY radiographic feature distinguishing chondrosarcoma from enchondroma; also: pain in adult + size >5 cm + progressive growth + cortical breach = chondrosarcoma
- Biopsy sampling error: cartilage paucicellular → easy to miss malignancy; biopsy does NOT exclude chondrosarcoma if imaging/clinical suspicious; multidisciplinary correlation mandatory
- Chemotherapy: NO benefit for conventional chondrosarcoma (all grades); RT limited benefit (cartilage radioresistant); surgery only; exceptions: dedifferentiated (chemo for high-grade component) and mesenchymal (Ewing-type chemo)